Literature DB >> 20362385

ERSPC and PLCO prostate cancer screening studies: what are the differences?

Fritz H Schröder, Monique J Roobol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20362385     DOI： 10.1016/j.eururo.2010.03.033

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  25 in total

1.  Optimization of PSA screening policies: a comparison of the patient and societal perspectives.

Authors:  Jingyu Zhang; Brian T Denton; Hari Balasubramanian; Nilay D Shah; Brant A Inman
Journal:  Med Decis Making       Date:  2011-09-20       Impact factor: 2.583

2.  Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.

Authors:  Sigrid Carlsson; Andrew J Vickers; Monique Roobol; James Eastham; Peter Scardino; Hans Lilja; Jonas Hugosson
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

3.  Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.

Authors:  Roman Gulati; Eric J Feuer; Ruth Etzioni
Journal:  Am J Epidemiol       Date:  2016-06-29       Impact factor: 4.897

4.  Lethal Prostate Cancer in the PLCO Cancer Screening Trial.

Authors:  Jonathan Shoag; Sameer Mittal; Joshua A Halpern; Douglas Scherr; Jim C Hu; Christopher E Barbieri
Journal:  Eur Urol       Date:  2016-05-07       Impact factor: 20.096

Review 5.  Screening for prostate cancer: early detection or overdetection?

Authors:  Andrew J Vickers; Monique J Roobol; Hans Lilja
Journal:  Annu Rev Med       Date:  2011-11-03       Impact factor: 13.739

6.  Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.

Authors:  Jonas Hugosson; Rebecka Arnsrud Godtman; Sigrid V Carlsson; Gunnar Aus; Anna Grenabo Bergdahl; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja
Journal:  Scand J Urol       Date:  2017-12-18       Impact factor: 1.612

Review 7.  Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.

Authors:  Daniel L J Thorek; Michael J Evans; Sigrid V Carlsson; David Ulmert; Hans Lilja
Journal:  Thromb Haemost       Date:  2013-08-01       Impact factor: 5.249

8.  Insights from the PLCO trial about prostate cancer screening.

Authors:  Roman Gulati; Peter C Albertsen
Journal:  Cancer       Date:  2016-12-01       Impact factor: 6.860

9.  The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

Authors:  Harry J de Koning; Roman Gulati; Sue M Moss; Jonas Hugosson; Paul F Pinsky; Christine D Berg; Anssi Auvinen; Gerald L Andriole; Monique J Roobol; E David Crawford; Vera Nelen; Maciej Kwiatkowski; Marco Zappa; Marcos Luján; Arnauld Villers; Tiago M de Carvalho; Eric J Feuer; Alex Tsodikov; Angela B Mariotto; Eveline A M Heijnsdijk; Ruth Etzioni
Journal:  Cancer       Date:  2017-12-06       Impact factor: 6.860

10.  Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality.

Authors:  Xiaoye Zhu; Pim J van Leeuwen; Erik Holmberg; Meelan Bul; Sigrid Carlsson; Fritz H Schröder; Monique J Roobol; Jonas Hugosson
Journal:  J Med Screen       Date:  2012-09       Impact factor: 2.136
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.